NewAmsterdam Pharma Co NV (FRA:KH6) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Debt-to-Equity?

NewAmsterdam Pharma Co NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.06 Mil. NewAmsterdam Pharma Co NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. NewAmsterdam Pharma Co NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €264.46 Mil. NewAmsterdam Pharma Co NV's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's Debt-to-Equity or its related term are showing as below:

FRA:KH6's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

NewAmsterdam Pharma Co NV Debt-to-Equity Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Debt-to-Equity Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-3.26

NewAmsterdam Pharma Co NV Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of NewAmsterdam Pharma Co NV's Debt-to-Equity

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Debt-to-Equity falls into.

NewAmsterdam Pharma Co NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NewAmsterdam Pharma Co NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.055	+	0)	/	264.456
	=	0.00

NewAmsterdam Pharma Co NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.055	+	0)	/	264.456
	=	0.00

NewAmsterdam Pharma Co NV (FRA:KH6) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NewAmsterdam Pharma Co NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NAMS:USA KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines